Evidence map›Paper›PMID 37355276›Full record

SynthesisBMJ open2023

Effects of metformin on bone mineral density and bone turnover markers: a systematic review and meta-analysis.

Jinhua Hu, Jingjie Han, Min Jin, Jing Jin, Jialei Zhu

Registry-linked trialOpen access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06856369 (Clinical Efficacy of 1% Metformin and Alendronate Gel in Adjunct to Fibrin in Chronic Periodontitis), which is not on this map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06856369 phase4active not recruitingnot on this mapstarted 2025, after this paper: background citation

Clinical Efficacy of 1% Metformin and Alendronate Gel in Adjunct to Fibrin in Chronic Periodontitis

TypeinterventionalSponsorBahria UniversityRan2025 to 2027Enrolled120ConditionsAlveolar Bone Loss Associated Chronic PeriodontitisArmsPlatelet rich fibrin, Metformin hydrochloride powder, alendronate sodium powder
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. The direct targets of metformin in diabetes and beyond.Trends in endocrinology and metabolism: TEM · 2025
    Review
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jinhua HuDepartment of Pharmacy, Shanghai Fourth People's Hospital Affiliated to Tongji University, Shanghai, Shanghai, China.
Jingjie HanDepartment of Pharmacy, Shanghai Fourth People's Hospital Affiliated to Tongji University, Shanghai, Shanghai, China.
Min JinDepartment of Pharmacy, Shanghai Fourth People's Hospital Affiliated to Tongji University, Shanghai, Shanghai, China.
Jing JinObstetrics and Gynecology Hospital of Fudan University, Shanghai, Shanghai, China zhujialei7582@fckyy.org.cn jinjing6974@fckyy.org.cn.
Jialei ZhuObstetrics and Gynecology Hospital of Fudan University, Shanghai, Shanghai, China zhujialei7582@fckyy.org.cn jinjing6974@fckyy.org.cn.ORCID 0000-0003-0029-5171
Tongji University · CNObstetrics and Gynecology Hospital of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesMetformin is associated with osteoblastogenesis and osteoclastogenesis. This study aims to investigate the impacts of metformin therapy on bone mineral density (BMD) and bone turnover markers.

designSystematic review and meta-analysis of randomised controlled trials.

methodsSearches were carried out in PubMed, EMBASE, Web of science, Cochrane library, ClinicalTrials.gov from database inception to 26 September 2022. Two review authors assessed trial eligibility in accordance with established inclusion criteria. The risk of bias was assessed using the Cochrane Risk of Bias tool (RoB V.2.0). Data analysis was conducted with Stata Statistical Software V.16.0 and Review Manager Software V.5.3.

resultsA total of 15 studies with 3394 participants were identified for the present meta-analysis. Our pooled results indicated that metformin had no statistically significant effects on BMD at lumbar spine (SMD=-0.05, 95% CI=

conclusionThis meta-analysis indicated that metformin had no significant effect on BMD. Metformin decreased some bone turnover markers as N-terminal propeptide of type I procollagen and C-terminal telopeptide of type I collagen. But the outcomes should be interpreted with caution due to several limitations.

Indexed as

Bone DensityMetforminBone RemodelingCollagen Type IHumansLumbar VertebraeCollagen Type IMetforminProcollagen Type Icalcium & bonediabetes & endocrinologysystematic review

Identifiers

PMID37355276
PMCPMC10314630
OpenAlexW4381884180

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.